<DOC>
	<DOCNO>NCT01338012</DOCNO>
	<brief_summary>This study conduct examine immune response generate sipuleucel-T subject previously treat sipuleucel-T androgen dependent setting . The study also assess safety receive 3 additional infusion sipuleucel-T . This open-label , uncontrolled , multicenter study , conduct 14 clinical trial site . The anticipated duration study approximately 6 year .</brief_summary>
	<brief_title>Sipuleucel-T Metastatic Castrate Resistant Prostate Cancer ( CRPC ) Patients Previously Treated Dendreon Study P-11 ( NCT00779402 )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Previously randomize Dendreon 's P11 study ( NCT00779402 ) receive least one infusion sipuleucelT Radiologic evidence metastasis Castrate resistant prostate cancer . Subjects must current historical evidence disease progression concomitant surgical medical castration , demonstrate PSA progression OR progression measurable disease OR progression nonmeasurable disease Castrate level testosterone ( &lt; 50 ng/dL ) achieve via medical surgical castration Adequate hematologic function Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 Treatment chemotherapy within 3 month prior registration Treatment systemic corticosteroid , external beam radiation therapy , investigational product prostate cancer within 28 day prior registration Current imminent pathologic longbone fracture Known malignancy prostate cancer likely require treatment within 6 month follow registration A requirement systemic immunosuppressive therapy reason A history allergic reaction attribute compound similar chemical biologic composition sipuleucelT GMCSF Any infection require antibiotic therapy cause fever within 1 week prior registration Any surgery require general anesthetic within 28 day prior registration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>metastatic castrate resistant prostate cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>prostate</keyword>
	<keyword>immune therapy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>vaccine</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>antigen-presenting cell</keyword>
	<keyword>antigen present cell</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>PSA</keyword>
	<keyword>prostatic adenocarcinoma</keyword>
</DOC>